Takeda CEO Weber post-close presentation

[anonymous]

OBU to be disposed. How do JS and MC explain this?

They have different priorities. They’ll be in hawaii working on there tan this weekend.

 

[anonymous]

Everyone working sales positions here has a company car and they work during the day and say things to customers to try to increase the use of the products.

 

[anonymous]

I think neuro could lose people b/c over overlap. OBU is gone. The whole group.

Why the hell are they hiring all these FAMs then?

 

[anonymous]

Hemophilia keeps talking how thin and lean they are but they are over the top they they will face serious cuts reps have very few accounts and spend most days at home calling on SP's really ?

 

[anonymous]

Hemophilia keeps talking how thin and lean they are but they are over the top they they will face serious cuts reps have very few accounts and spend most days at home calling on SP's really ?

Hemophilia is far from lean. Too many of them

 

[anonymous]

See the link on the first post. Then read: https://www.biospace.com/article/ta...core-assets-to-offset-debt-of-the-shire-deal/

As BioSpace noted earlier this week, Weber is eying the potential of unloading $10 billion in assets to deleverage the $30 billion in debt it took on to acquire Shire. That means that the company will be divesting a significant amount of assets.

In his interview with Bloomberg, Weber said that 75 percent of the company’s business is considered a core asset. That leaves to 25 percent of the entirety of Takeda’s portfolio where the company will find assets that could be sold off to reduce some of the debt. Weber said the company has already begun a process of identifying some of the assets that it will use as a debt-saving tool. Now, the company needs to find some buyers who will be willing to acquire the assets for about $10 billion, Weber said.

“Some of these products are non-core for us, but might be core for others,” Weber told Bloomberg.

While Weber did not disclose any potential buyers, he noted that other pharma companies or equity firms could be in the running to pick up the assets. He noted that it will largely depend on the assets being sold off. Some of those have global applications, while others are more localized. The assets will likely determine the buyer, he noted.